# HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

> **NCT07232875** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 588 (estimated)

## Conditions studied

- KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

## Interventions

- **DRUG:** HRS-4642 + AG
- **DRUG:** HRS-4642 placebo + AG

## Key facts

- **NCT ID:** NCT07232875
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 588 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232875, "HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07232875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*